On March 16, 2018, Illumina, Inc. (“Plaintiff”) filed a complaint against Natera, Inc. (“Defendant”) asserting infringement of U.S. Patent No. 9,493,831 (“the ‘831 Patent”). The ‘831 Patent is assigned to the Plaintiff and is drawn to methods of fetal abnormality detection by selectively enriching non-random polynucleotide sequences. The Plaintiff is asserting that the Defendant is infringing the asserted patent by performing a non-invasive prenatal test for Down syndrome, including the Defendant’s “Panorama™ Natera Prenatal Screen”. The case remains pending and is captioned 5-18-cv-01662.
By: Jacqueline A. DiRamio